An Update on the Stimulant Shortage and Practical Guidance for the Pediatric Prescriber

Abstract

Get full access to this article

View all access options for this article.

References

Centers for Disease Control and Prevention. Attention-deficit/hyperactivity disorder (ADHD), data and statistics on ADHD. Updated November 19, 2024. Accessed January 15, 2025. https://www.cdc.gov/adhd/data/index.html

Bernardi

Faraone

Cortese

, et al. The lifetime impact of attention deficit hyperactivity disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Psychol Med. 2012;42(4):875-887.

Harpin

Mazzone

Raynaud

Kahle

Hodgkins

Long-term outcomes of ADHD: a systematic review of self-esteem and social function. J Atten Disord. 2016;20(4):295-305.

Wolraich

Hagan

Jr Allan

, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2019;144(4):e20192528.

Sultan

Correll

Schoenbaum

King

Walkup

Olfson

National patterns of commonly prescribed psychotropic medications to young people. J Child Adolesc Psychopharmacol. 2018;28(3):158-165.

Strathearn

Liu

Yang

Bao

Twenty-year trends in diagnosed attention-deficit/hyperactivity disorder among US children and adolescents, 1997-2016. JAMA Netw Open. 2018;1(4):e181471.

Danielson

Claussen

Bitsko

, et al. ADHD prevalence among U.S. children and adolescents in 2022: diagnosis, severity, co-occurring disorders, and treatment. J Clin Child Adolesc Psychol. 2024;53(3):343-360.

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.

Chai

Goyal

, et al. Trends in incident prescriptions for behavioral health medications in the US, 2018-2022. JAMA Psychiatry. 2024;81(4):396-405.

10.

Huskamp

Uscher-Pines

Raja

Normand

Mehrotra

Busch

AB.

Trends in use of telemedicine for stimulant initiation among children and adults. Psychiatr Serv. 2024;75(7):630-637.

11.

Joint DEA FDA Letter [press release]. US Food Drug Administration. Published August 1, 2023. https://www.dea.gov/sites/default/files/2023-08/DEA%20and%20FDA%20Issue%20Joint%20Letter%20to%20the%20Public.pdf

12.

Park

Conti

Wosinska

, et al. Building resilience into US prescription drug supply chains. Health Affairs Forefront. January 30, 2023:8. doi:10.1377/forefront.20230126.864137.

13.

Specialist Pharmacy Service. Prescribing available medicine to treat ADHD. Accessed January 15, 2025. https://www.sps.nhs.uk/articles/prescribing-available-medicines-to-treat-adhd/

14.

Department of Health and Ages Care TGA. Medicine shortages report database. Accessed January 15, 2025. https://apps.tga.gov.au/Prod/msi/Search/Details/methylphenidate-hydrochloride

15.

Simpson

Yik

Managing medicine shortages. Aust Prescr. 2024;47(5):148-152.

16.

Johnson

Stjepanovic

Leung

Chan

GCK

. “Everything’s a challenge“: an interview study of ADHD individuals in the midst of the prescription stimulant shortage. J Atten Disord. 2025;29(2):120-127.